AbbVie's Emraclidine For Schizophrenia 'Surprisingly Disappoints,' Analyst Says Pipeline Is UnderappreciatedBenzinga • 11/11/24
AbbVie Stock Slips As $9 Billion Schizophrenia Studies Flunk, Bristol-Myers Stock SurgesBenzinga • 11/11/24
AbbVie Stock Falls Sharply as Schizophrenia Therapy Shows No ‘Significant' ImprovementBarrons • 11/11/24
AbbVie and EvolveImmune Therapeutics Announce Collaboration and Option-to-License Agreement to Develop Next-Generation Cancer BiotherapeuticsGlobeNewsWire • 10/31/24